The historical rank and industry rank for Nectar Lifesciences's Gross Margin % or its related term are showing as below:
NSE:NECLIFE'
s Gross Margin % Range Over the Past 10 Years
Min: 6.57 Med: 17.17 Max: 22.01
Current: 6.57
During the past 13 years, the highestGross Margin % of Nectar Lifesciences was 22.01%. The lowest was 6.57%. And the median was 17.17%.
NSE:NECLIFE's Gross Margin % is ranked worse than 97.14% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:NECLIFE: 6.57
Nectar Lifesciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nectar Lifesciences was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nectar Lifesciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nectar Lifesciences Gross Margin % Related Terms
Nectar Lifesciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nectar Lifesciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NECLIFE vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nectar Lifesciences (NSE:NECLIFE) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nectar Lifesciences and its competitors. Over the past decade, Nectar Lifesciences' Gross Margin % has ranged from 6.57 to 22.01. According to the industry distribution chart, Nectar Lifesciences ranks #916 out of 943 companies in the Drug Manufacturers industry, placing it in the top 97.1%.
Is Nectar Lifesciences' Gross Margin % too high?
Nectar Lifesciences' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 6.57 to a high of 22.01. Based on the distribution chart, Nectar Lifesciences ranks #916 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #916 out of 943 companies for Gross Margin %. This places Nectar Lifesciences in the lower half of its industry. The industry median Gross Margin % is 48.54. Historically, Nectar Lifesciences' own Gross Margin % has ranged from 6.57 to 22.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nectar Lifesciences and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nectar Lifesciences's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹11.19 — trading 63.1% above its estimated fair value. The current Gross Margin % is 0.00%. Nectar Lifesciences' overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued.
The current stock price of ₹11.19 is trading 63.1% above its estimated GF Value™ of ₹6.86.
GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.
Key valuation signals for NSE:NECLIFE:
Gross Margin %: 0.00%
GF Value™: ₹6.86 vs. price of ₹11.19 (63.1% above fair value)
No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
57GF Score
Get the complete analysis for NSE:NECLIFE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
